Conference Coverage
Conference Coverage
VOYAGER PAD: Paclitaxel-coated devices don’t increase mortality
“I think this study is a game changer. And I think the paclitaxel game is over.” – Dr. Frank Veith
Conference Coverage
Link between vitamin D and ICU outcomes unclear
When patients are admitted to the ICU, some biomarkers in the body are too high and others are too low. Vitamin D is often too low.
Conference Coverage
MitraClip effective for post-MI acute mitral regurgitation with cardiogenic shock
“The development of cardiogenic shock should not preclude percutaneous mitral valve repair in this scenario.” – Dr. Rodrigo Estevez-Loureiro
Conference Coverage
Intravascular lithotripsy hailed as ‘game changer’ for coronary calcification
Positive results reported from the U.S. pivotal Disrupt CAD III study sets stage for regulatory approval.
Conference Coverage
Fauci: Cautious optimism for COVID-19 vaccine by end of 2020
Top health official is “cautiously optimistic” for vaccine distribution before end of year, pending favorable safety and efficacy data.
Conference Coverage
NACMI: Clear benefit with PCI in STEMI COVID-19 patients
Angiography fell off but door-to-balloon times haven’t suffered, even with the pandemic, according to initial results from the North American...
Latest News
Substance in tears could be used for diabetes monitoring
Measuring glycoalbumin in tears could someday be a way for patients with diabetes to monitor their glucose levels noninvasively.
Conference Coverage
Ticagrelor monotherapy beats DAPT in STEMI
One-year results of the randomized TICO-STEMI trial suggests aspirin can be dropped safely after 3 months, but the findings need confirmation,...
Conference Coverage
T2D treatments create tension between glycemic and cardiovascular goals
Recent society guidelines clash on whether metformin or newer drug classes should start first when treating patients with type 2 diabetes.
Conference Coverage
Repurposing cardiovascular drugs for serious mental illness
What these agents have in common, the investigators observed, is that they act on inflammation and potentially on the stress response system.
Conference Coverage
Benefit of rivaroxaban after limb revascularization greatest in those with comorbid CAD
New results from the landmark VOYAGER PAD trial identify which patients benefit most from adding rivaroxaban after limb revascularization.